Skip to main content

Table 4 Univariate analysis of 2-year clinical outcomes

From: Outcome of haploidentical versus matched sibling donors in hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

  RI NRM LFS OS GRFS aGVHD grade II–IV aGVHD grade III–IV cGVHD ext. cGVHD
MSD 31.6% [29.2–34%] 13% [11.4–14.7%] 55.4% [52.8–57.9%] 67.4% [64.8–69.8%] 39% [36.4–41.5%] 28.9% [26.8–31.1%] 10.5% [9.1–12%] 38.8% [36.3–41.3%] 19.5% [17.5–21.7%]
Haplo 26% [21.5–30.8%] 22.9% [18.8–27.3%] 51% [45.7–56.2%] 58.8% [53.3–63.9%] 40.6% [35.4–45.7%] 36.3% [31.5–41.1%] 15.2% [11.9–19%] 32% [27.1–37.1%] 11.9% [8.6–15.8%]
p 0.017 0.001 0.07 0.001 0.74 0.002 0.005 0.009 0.001
  1. RI, relapse incidence; NRM, non-relapse mortality; LFS, leukemia-free survival; OS, overall survival; GVHD, graft versus host disease; GRFS, GVHD-free/relapse-free survival; KPS, Karnofsky performance status; ATG, anti-thymocyte globulin; PTCy, post-transplant cyclophosphamide; RIC, reduced intensity conditioning; MAC, myeloablative conditioning; PB, peripheral blood; BM, bone marrow